- Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibody-based therapeutics.
- Celldex's new pipeline is now made up of 3 Phase 1 immunotherapies/targeted biologics aiming to primarily treat various cancers and autoimmune diseases.
- Celldex has returned to a stable financial position after 2Q 2020's capital raise of $165.1M for +21.4M shares (+120.90% share dilution) bringing cash to $199.6M (2-3 years of runway).
- Celldex's next catalyst is CDX-0159's initial trial data expected to be reported at the end of 1Q 2021.
- In summary, the author projects Celldex Therapeutics, Inc. (NASDAQ: CLDX) as a reasonable "buy" at a 6-8 year price target of $74.8 (+330% upside).
For further details see:
Celldex: New Monoclonal Therapeutic Line, 1Q21's CDX-0159's Initial Trial Data, And More